Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to $2.4 million.

  • Standard Biotools' Non-Current Deffered Revenue fell 9276.05% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 9276.05%. This contributed to the annual value of $32.7 million for FY2024, which is 82823.86% up from last year.
  • Standard Biotools' Non-Current Deffered Revenue amounted to $2.4 million in Q3 2025, which was down 9276.05% from $2.8 million recorded in Q2 2025.
  • Standard Biotools' 5-year Non-Current Deffered Revenue high stood at $33.9 million for Q1 2024, and its period low was $2.4 million during Q3 2025.
  • In the last 5 years, Standard Biotools' Non-Current Deffered Revenue had a median value of $5.8 million in 2022 and averaged $12.1 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 84075.99% in 2024, then crashed by 9276.05% in 2025.
  • Quarter analysis of 5 years shows Standard Biotools' Non-Current Deffered Revenue stood at $6.0 million in 2021, then plummeted by 36.04% to $3.8 million in 2022, then dropped by 7.76% to $3.5 million in 2023, then surged by 828.24% to $32.7 million in 2024, then tumbled by 92.76% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $2.8 million for Q2 2025, and $32.5 million during Q1 2025.